CFSMX
Price
$13.84
Change
+$0.05 (+0.36%)
Updated
Sep 17 closing price
Net Assets
290.92M
JVMRX
Price
$30.99
Change
+$0.09 (+0.29%)
Updated
Sep 17 closing price
Net Assets
23.27B
Interact to see
Advertisement

CFSMX vs JVMRX

CFSMX vs JVMRX Comparison Chart in %
View a ticker or compare two or three
VS
CFSMX vs. JVMRX commentary
Sep 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CFSMX is a Hold and JVMRX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JVMRX has more cash in the bank: 23.3B vs. CFSMX (291M). JVMRX pays higher dividends than CFSMX: JVMRX (0.74) vs CFSMX (0.42). CFSMX was incepted earlier than JVMRX: CFSMX (11 years) vs JVMRX (15 years). CFSMX (0.89) is less costly to investors than JVMRX (0.75). JVMRX is a more actively managed with annual turnover of: 48.00 vs. CFSMX (28.00). JVMRX has a lower initial minimum investment than CFSMX: JVMRX (1000000) vs CFSMX (100000000). JVMRX annual gain was more profitable for investors over the last year : 3.32 vs. CFSMX (2.17). JVMRX return over 5 years is better than : 15.74 vs. CFSMX (-11.92).
CFSMXJVMRXCFSMX / JVMRX
Total Expense Ratio0.850.74115%
Annual Report Gross Expense Ratio0.890.75119%
Fund Existence11 years15 years-
Gain YTD8.32712.52766%
Front LoadN/AN/A-
Min. Initial Investment100000000100000010,000%
Min. Initial Investment IRAN/AN/A-
Net Assets291M23.3B1%
Annual Yield % from dividends0.420.7456%
Returns for 1 year2.173.3265%
Returns for 3 years1.3821.157%
Returns for 5 years-11.9215.74-76%
Returns for 10 years33.5559.2557%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNSX25.670.17
+0.67%
MFS Equity Income R2
DWGFX16.400.03
+0.18%
American Funds Dvlpg Wld Gr&Inc F-1
FIMKX51.78N/A
N/A
Fidelity Advisor Focused Em Mkts I
BUFOX17.86N/A
N/A
Buffalo Early Stage Growth Fd
JMNSX15.12N/A
N/A
JPMorgan Research Market Neutral I